ORKA
Oruka Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +16.7% ·
share flow +30.0% ·
net new positions +14.3%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +25 | 38.88M | $3.70B | +30 | −5 |
| Q1 2026 | 76 | +12 | 25.47M | $1.25B | +17 | −5 |
| Q4 2025 | 63 | +1 | 24.86M | $753.58M | +1 | — |
| Q3 2025 | 15 | +1 | 17.63M | $338.97M | +3 | −2 |
| Q2 2025 | 11 | 0 | 11.37M | $127.46M | +1 | −1 |
| Q1 2025 | 8 | +1 | 1.39M | $14.29M | +2 | −1 |
| Q4 2024 | 7 | +1 | 2.25M | $43.63M | +1 | — |
| Q3 2024 | 5 | +5 | 1.06M | $25.93M | +5 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 1.33M | +374.5% | $25.73M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Point72 Asset Management ✦ | 360.73K | -25.2% | $6.99M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 342.42K | +2348.6% | $6.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 95.09K | +15.8% | $1.84M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 69.20K | -65.4% | $1.34M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 30.30K | New | $587,614 | 0.0% | New | 1 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (passive) | 25.02K | — | $485,196 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $587,614 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 183 holders, 52.32M shares, $2.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 601 sh · $56,760
Officer · 3.83K sh · $357,592
Officer · 2.90K sh · $267,870
Officer · 533 sh · $51,035
Officer · 2.67K sh · $254,196
Officer · 560 sh · $53,598
Officer · 1.04K sh · $99,443
Officer · 906 sh · $86,713
Officer, Director · 2.45K sh · $234,681
Officer · 947 sh · $90,637
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
19.5% of class · View original SEC filing ↗